Intramedullary Osteosarcoma Treatment Market size is anticipated to reach USD 1 Billion by the end of 2036, growing at a CAGR of 5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of intramedullary osteosarcoma treatment was over USD 513 Million. Intramural osteosarcoma, also known as osteogenic sarcoma, is the most common type of bone cancer and develops in the cells that make new bone. For instance, approximately 3,970 new cases were detected in adult Americans in 2023. Osteosarcoma can affect any bone in the body, although it most commonly affects the long bones, such as the hands and legs. Signs and symptoms of osteosarcoma include regional bone pain and edema. Throughout the projection period, there will likely be a greater need for intramedullary osteosarcoma treatment due to the high incidence of osteosarcoma around the world.
Moreover, by raising the proportion of cases identified at an early stage, early detection activities such as screening programs for high-risk persons or those with predisposing characteristics can support the market's overall expansion. Additionally, early discovery makes it possible to intervene sooner, which improves treatment results and raises survival rates. Therefore, these factors are propelling the growth of the intramedullary osteosarcoma treatment market.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~ 5% |
|
Base Year Market Size (2023) |
~ USD 513 Million |
|
Forecast Year Market Size (2036) |
~ USD 1 Billion |
|
Regional Scope |
|
Treatment Type (Chemotherapy, Combination Therapy, Targeted Therapy)
The targeted therapy segment in the intramedullary osteosarcoma treatment market is expected to hold a share of 44% during the forecast period. These therapies are designed to specifically target molecular alterations or pathways that drive cancer growth, making them more precise and potentially less toxic than traditional chemotherapy. Also, ongoing research and clinical trials are evaluating the safety and efficacy of targeted therapies in intramedullary osteosarcoma. For instance, Topline results from the LIBRETTO-431 study, which compared Retevmo to platinum-based chemotherapy plus pemetrexed, with or without pembrolizumab, as an initial treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that was rearranged during transfection (RET) were released by Eli Lilly and Company. With a statistically significant and clinically relevant improvement in progression-free survival (PFS), the trial achieved its primary aim. Furthermore, advances in molecular profiling technologies and understanding of the genetic and molecular mechanisms underlying osteosarcoma have led to the identification of potential targets for therapy.
Distribution Channels (Hospital Pharmacies, University Hospitals Pharmacies)
The hospital pharmacies segment in the intramedullary osteosarcoma treatment market is anticipated to hold the largest share of 54% during the forecast period. The availability of specific drugs and chemotherapeutic treatments for the treatment of intramedullary osteosarcoma is responsible for the rise. In addition, there is an increasing need for healthcare services, particularly prescription drugs, as the population ages and grows. As per a report, 771 million individuals worldwide were 65 years of age or older in 2022, making up about 10% of the world's population. With its steady growth, this market is predicted to reach sixteen percent by the year 2050. Hospital pharmacies are essential to the general expansion of the healthcare sector because they provide patients with pharmaceutical care inside hospital settings. Furthermore, hospital pharmacies are growing to fulfill these standards and implementing cutting-edge technologies like automated dispensing systems and electronic medication records in response to the growing emphasis on medication management and adherence. The provision of specialty services including compounding, oncology pharmacy, and clinical pharmacy services is another factor fueling the market's expansion.
Our in-depth analysis of the global market includes the following segments:
|
Treatment Type |
|
|
End-user |
|
North American Market Forecast
The North American intramedullary osteosarcoma treatment market is anticipated to hold a share of 37% during the forecast period. It is expected that the region will increase its market share in the future because there are multiple clinical studies for bone cancer treatments underway, most of which are in the United States. Numerous researchers are testing new chemotherapy treatments. Scholars are already contemplating innovative uses for the assortment of presently approved medications. For example, scientists are investigating whether mixing bone cement and the bisphosphonate zoledronic acid (Zometa), which is used to fill the gap left by a giant cell tumor, can reduce the risk of the tumor growing back in that region. Throughout the forecast period, these factors are expected to boost the market.
European Market Statistics
intramedullary osteosarcoma treatment market in Europe is expected to grow with the second-largest share of 27% by the end of 2036. While osteosarcoma is a rare cancer, its incidence has been gradually increasing, contributing to the growth of the market. The region has stringent regulatory standards for drug approval and patient safety. Adoption of intramedullary osteosarcoma treatment is becoming more common in industrialized nations due to rising government spending on healthcare. A potential driver of the intramedullary osteosarcoma market's expansion may be the disease's rising prevalence rate.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?